Company
Ergomed PLC
LON:ERGO
Ergomed PLC provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. The company's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO).
204 stories · page 8 of 11
Falcon Oil surges on hint over Aussie gas drilling
Main share price risers and fallers in London around 3.30pm include Falcon Oil, Cap-XX
Drug developer Ergomed set to kick off phase II trial on treatment for surgical bleeding
Sales of PeproStat can be as high as US$500mln believes Ergomed
Investments and investor services
FTSE 100 ends little changed as UK lines up on Brexit grid
The druggies and miners were on offer early on – although the movements were barely perceptible on a lacklustre Monday morning.
Archive
Proactive news round-up: Ithaca Energy, Ergomed, Amryt Pharmaceuticals ...
A glance at some of the stories on the Proactive newswire today.
Ergomed announces positive top-line results from Phase II insomnia treatment trial
The group said the drug Lorediplon met the primary endpoint with high statistical significance, indicating the drug has “strong efficacy in sleep maintainance".
Ergomed expects 'pivotal ' endometrial cancer trial result in April
Ergomed's clinical services arm carried out the trial
Archive
Proactive news highlights: DekelOil, dotDigital, FairFX and more…
DekelOil confirms maiden dividend; dotDigital sees big pick-up in client spending; FairFX Group says 2016 revenues are ahead of expectations; plus much more…
Ergomed predicts more to come as revenues surge
Revenues in 2016 were £38mln, up 26%, with an order backlog at the end of the year of £70mln.
Archive
Proactive news round-up: Sound Energy, Matals Exploration, Acal ...
A snapshot of the stories on the Proactive newswire today
Proactive news round-up: Strategic Minerals, CloudTag, Frontier IP...
A round-up of today's small cap stories on the Proactive newswire
Ergomed names new chairman designate
Peter George has become chairman designate with immediate effect at Ergomed Plc (LON:ERGO) after Rolf Stahel notified the board he would retire at the expiry of his three year term on March 31 next year.
Immupharma among the small cap pharmas in focus on Wednesday
Immupharma among the small cap pharmas in focus on Wednesday, alongside Futura Medical, Horizon Discovery Group, and Summit Therapeutics.
Ergomed welcomes expansion of Sickle Cell Disease study
Modus Therapeutics, Ergomed's co-development partner on sevuparin, a treatment for Sickle Cell Disease, has been given the all-clear to also enrol teenagers into its clinical study.
Archive
Brokers: UK pharma giants in good shape if Clinton wins says Citigroup
“From a legislative angle, we continue to prefer names with either limited part D exposure [US Medicare] or heavier contribution of non-pharma assets."
Ergomed racing away with development pipeline
The trial is expected to start in 2017 and estimated to last around two years.
Ergomed to team up with Asarina Pharma in phase IIb trial
Ergomed will run and partly fund the phase IIb trial of Asarina’s premenstrual syndrome treatment Sepranolone in return for an equity stake in the firm
Small Cap highlights: Sareum leads Monday’s stand-out small cap biotech stocks
Sareum, Faron, WideCells, Abzena and Ergomed were among Monday's small cap highlights
Ergomed’s partner Modus Therapeautics set for stock market IPO
Ergomed co-invests in the trial in return for equity in the partner, and as a result it is a shareholder in the soon-to-list company.